Salute e Benessere
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXi Biologics developed WuXia293 by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293 demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism.
The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293 offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages. Furthermore, the WuXia293 cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293 platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution.
The launch of the WuXia293 platform has further strengthened the service capabilities of WuXi Biologics' WuXia™ platform family. Besides WuXia293 , the WuXia™ platform has already derived multiple cell line development platforms, including WuXia Plus™ and WuXia RidGS™, to address customers' diverse requirements.
, commented, "We are excited to launch an industry-leading solution that significantly enhances the development of advanced therapeutics. WuXia293 stands as a powerful testament to WuXi Biologics' unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry. Once again we are reaffirming our promise to enable our clients in accelerating the delivery of innovative biologics to patients worldwide. "
WuXia™ is a proven, high-yield (up to about 11 g/L) mammalian cell line platform family developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia™ platform family have generated over 1000 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing as of 2024.
The WuXia™ platform family include WuXia Plus™ for developing and manufacturing afucosylated antibodies to elicit an enhanced ADCC response, WuXia RidGS™ for non-antibiotic cell line development, and the latest WuXia293 for expressing difficult-to-express molecules built on HEK293 cell lines. The WuXia™ cell line development platform family continue to expand to cater to the diverse needs of global customers.
View original content:https://www.prnewswire.co.uk/news-releases/wuxi-biologics-launches-hek-293-stable-cell-line-platform-wuxia293-stable-for-development-and-manufacturing-of-difficult-to-express-molecules-302526308.html